Founded in 1993
  Year: 2000 | Volume: 8 | Issue: 4 | Pages: 161-163
  Original Article
John VAKALIKOS, Dimitrios RADOPOULOS, Alexander H. KORTSARIS, Grammati GALAKTIDOU, Vasiliki VALLA, Nikolaos DIMASIS, Athanasios KALINDERIS
  Background: Transitional cell bladder tumors are common and they have rising incidence. Most of them appear, at the beginning, as superficial ones. Superficial bladder tumors, despite the favorable prognosis will recur in 70% of the cases within 36 months after the transurethral resection (TUR) if no additional treatment with intravesical instillation is administered. Recurrences increase the risk of disease progression and the appearance of infiltratory tumors. Among the various instillation protocols active worldwide, interferon-alfa-2b (INTRON) has been used and many studies report encouraging results, thus establishing it as a potent agent for intravesical instillation therapy.
Materials and Methods: The measurement of 2'5'oligo(A)synthetase was estimated by following the conversion of 3H-labelled ATP to adenosine oligomers as previously described by the authors. Frozen tissues from bladder biopsies were used as source obtained from more than thirty patients who were enrolled in the protocol.
Results: The most important finding of our observations is the excellent correlation between the induction of 2'5'oligo(A)synthetase and the response to the therapy. Ninety percent of the responders have increased level of the enzyme. No difference was observed in comparison to patients that received combined therapy with IFNalfa-2b, plus epirubicin. The control values of the enzyme are increased in comparison with the levels of the enzyme in other tissues.
Conclusion: The results of the induction of 2'5'oligo(A)synthetase could be used as a novel reliable marker for monitoring patients with superficial bladder tumors which are under a protocol with IFNalfa-2b instillation.
  Key words: 2'5'oligo(A)synthetase; Bladder cancer; IFNalfa
  Read full text in PDF [Full Text]
Next article

Previous article

Table of contents

Browse all Volumes

Search all Volumes
By keywords
By authors

  Search AoO for:

  Related articles in AoO:
About Journal | Editorial Board | Editorial Policy | Instructions for Authors | Open Access | Advertising | Payed issues | Article Submission Charge | Contact
Founder, owner and publisher: Oncology Institute of Vojvodina, Serbia
Online since 1997 (Abstracts only); 2000 (Abstracts and Full text)
ISSN: 0354-7310 eISSN: 1450-9520